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Abstract
Immune cells develop endotoxin tolerance (ET) after prolonged stimulation. ET increases the level 
of a repression mark H3K9me2 in the transcriptional-silent chromatin specifically associated with 
pro-inflammatory genes. However, it is not clear what proteins are functionally involved in this 
process. Here we show that a novel chromatin activity based chemoproteomic (ChaC) approach 
can dissect the functional chromatin protein complexes that regulate ET-associated inflammation. 
Using UNC0638 that binds the enzymatically active H3K9-specific methyltransferase G9a/GLP, 
ChaC reveals that G9a is constitutively active at a G9a-dependent mega-dalton repressome in 
primary endotoxin-tolerant macrophages. G9a/GLP broadly impacts the ET-specific 
reprogramming of the histone code landscape, chromatin remodeling, and the activities of select 
transcription factors. We discover that the G9a-dependent epigenetic environment promotes the 
transcriptional repression activity of c-Myc for gene-specific co-regulation of chronic 
inflammation. ChaC may be also applicable to dissect other functional protein complexes in the 
context of phenotypic chromatin architectures.
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Activation of inflammation is the key host response to microbial challenge, yet excessive 
production of proinflammatory cytokines can lead to tissue/organ damage or autoimmune 
diseases1, 2. To minimize harmful effects caused by the continual presence of environmental 
stimuli, pre-exposed cells suppress cytokine production to become transiently unresponsive. 
However, this acquired immune tolerance is a double-edged sword, both protecting the host 
from infection/damage and, when dysregulated, contributing directly to various 
inflammation-associated pathologies3. Development of tolerance to endotoxin or 
lipopolysaccharide (LPS) is a major molecular feature of the pathogenesis of many chronic 
diseases including asthma, sepsis, and cancer, as people experiencing endotoxin tolerance 
(ET) are immune-compromised4, 5. Recent studies have revealed that control of 
inflammation is achieved primarily epigenetically in a gene-specific manner, whereby, with 
prolonged LPS stimulation, chromatin associated with pro-inflammatory or ‘tolerizeable’ 
genes (T-genes) becomes transcriptionally silenced6, 7. Unknown, however, are the 
functional constituents of the inflammation-phenotypic chromatin architecture that directly 
participate in transcription regulation of select genes.
Histone post-translational modifications (PTMs), such as acetylation, phosphorylation, 
methylation, determine the functional state of chromatin, which eventually control 
chromatin-mediated transcription8. Meanwhile, the levels of particular histone PTM(s) are 
regulated by corresponding histone-modifying enzymes, whose activities vary under 
different cell states9. Specifically, within transcriptional-silenced chromatin, dimethylated 
lysine 9 on histone H3 (H3K9me2), a code for transcriptional repression, is higher in 
abundance compared to the transcriptional-active chromatin of LPS-responsive cells10, 
implicating that the H3K9me2 writer, a histone methyltransferase (HMTase) G9a11, 12 is 
more enzymatically active in LPS-tolerant macrophages. Further, G9a was identified as a 
common component of different protein co-repressor complexes13,14,15,16 and was also 
found to interact with various chromatin effectors17. Additionally, a growing number of 
non-histone substrates of G9a has been identified18. These data led us to hypothesize that 
within transcriptional-silenced chromatin, G9 exercises a wide-spread function in gene-
specific transcriptional regulation by coordinating a chromatin writer assembly involving 
multiple, distinct protein complexes (or ‘complexome’)19.
Emerging activity-based protein profiling (ABPP) strategies provide functional assessment 
of particular classes of proteins/enzymes including kinases, proteases, phosphatases, 
glycosidases, and oxidoreductases in defined cell states20. Further, quantitative ABPP 
allows comparison of the target phenotypic activities with identification of their activity-
based complex companions in cells21. While the emergence of newly synthesized chemicals 
that show high specificity in recognizing different histone-modifying enzymes enables the 
proteome-wide analysis of their activities in various live cells22–25, the unique strength of 
emerging chemoprobes of corresponding histone-modifying enzymes needs to be explored 
to dissect various epigenetic protein machinery operating under defined phenotypic cell 
states.
Liu et al. Page 2













Here we use UNC063826, a substrate-competitive inhibitor/chemoprobe that selectively 
binds enzymatically active G9a, to design a novel chromatin-activity-based chemoproteomic 
(ChaC) approach to systematically characterize proteins specifically complexed with the 
phenotypic-active G9a within the gene-specific chromatin of defined transcriptional states. 
606 proteins are identified to have enhanced interactions with activated G9a within ET-
characteristic chromatin, while their associations with G9a are weakened or undetectable in 
acute-inflamed macrophages. This inflammation-phenotypic ChaC analysis indicates that 
chronically active G9a promotes assembly of an ET-characteristic complexome. Further 
characterization of our function-based ChaC proteomic findings reveals that chronic-active 
G9a not only coordinates the deposition of combinatorial methyl-lysine codes on H3 but 
also stabilizes select transcription factors in cross talk to promote their co-repression of 
select genes. Specifically, we discover a new G9a-dependent role of c-Myc in regulating 
select genes under chronic inflammation, whereby chronic-active G9a directs c-Myc toward 
a transcription repressor by stabilizing c-Myc within a gene-specific, methyl-lysine-rich 
chromatin environment. On a systems view within the chromatin associated with specific 
genes, chronic-active G9a/GLP preserve the integrity of the protein complexes for ET-
characteristic transcriptional repression or a protein ‘repressome’27. ChaC methodology 
reveals how this repressome complex is built, localized, and regulated in the gene-specific 
manner.
RESULTS
Histone H3 PTM is reprogrammed in LPS-tolerant macrophages
To determine exactly how histone H3 is differentially modified during the macrophage 
response to acute versus chronic LPS stimulation, we first used top-down MS28 to map the 
PTM landscape of full-length H3 from bone marrow-derived macrophages (BMDMs) under 
the following inflammatory states7: non-stimulated (naïve or ‘N’) cells, cells stimulated with 
a single high-dose LPS (LPS-responsive or ‘NL’), cells primed with a low-dose LPS (LPS-
tolerant or ‘T’), and LPS-tolerant cells re-stimulated with a high-dose LPS that mimics ET 
(‘TL’) (Supplementary Fig. 1a). Following histone extraction and HPLC purification of 
individual core histones (Supplementary Fig. 1b), different combinations of PTMs on full-
length H3.1 were identified by top-down FTICR-MS based on the accurate mass 
measurements28 (Supplementary Fig. 1c). We also used Velos LTQ-orbitrap to perform top-
down MS (Supplementary Fig. 2a) and select ion monitoring (SIM) ETD MS/MS on each of 
these peaks to sequence the PTM sites on H3. Specifically from non-stimulated BMDMs, 
through multi-layer SIM ETD MS/MS ‘purification’ (Supplementary Fig. 2b, 3a) we 
identified the pre-dominate species in Peak #2 as a multiply modified form of H3.1 
containing H3K4me2, K9me2, and K27me2 (Supplementary Fig. 3b). Also, an adjacent 
peak (Peak #1) at 14 Da upfield of Peak #2 contains a mixture with a population carrying an 
acetylation at lysine 9 (K9ac) along with H3K4me2 and K27me2 (the top panel, 
Supplementary Fig. 3b). Notably, the relative K9ac abundance was increased under NL but 
decreased in TL BMDMs, whereas the opposite in K9me2 abundance was found 
(Supplementary Fig. 1c, 2a). Nevertheless, all data identified the key PTM conversion at 
H3K9 with the TL-specific increase of K9me2 on H3. Because the methylation activity of 
G9a directly correlates with the accumulation of H3K9me2, combined MS results indicated 
Liu et al. Page 3













that, specifically in LPS-tolerized macrophages, G9a promotes acetylation-to-methylation 
conversion at H3K9.
G9a is activated within T-gene chromatins during ET
The inflammation-phenotypic PTM change at H3K9 also implied that the H3K9-targeting 
activity of G9a could be differentially regulated at T-gene promoters in TL versus NL cells. 
To clarify this, we first performed ChIP experiments with anti-K9me2 antibody on the 
BMDM set under different inflammatory states (Supplementary Fig. 4a). Coincident with 
the MS data (Supplementary Fig. 1, 2, 3), decreasing dimethylation and increasing 
acetylation of H3K9 were observed at both distal (cc) and proximal (dd) promoter regions of 
a T-gene (IL6) under NL. However, in ET macrophages, an increased H3K9me2 was 
observed at the same regions beyond TSS, indicating that the accumulation/occupancy of 
H3K9me2 on T-gene promoters during ET introduces a block for both transcription 
initiation and elongation of T-class genes (Supplementary Fig. 4b). Similarly, in ChIP 
analysis with anti-G9a antibody, dramatically enhanced binding of G9a to the promoter 
region ‘cc’ and the first intron ‘ee’ was observed during ET (Supplementary Fig. 4c), 
indicating that G9a is recruited to the cis-regulatory elements of IL6 and represses its 
expression (Supplementary Fig. 4d). To clarify the role of G9a in ET-specific dimethylation 
of H3K9, prior to LPS stimulation we treated BMDMs with UNC0638 that inhibits the 
methylation activity of the enzyme but causes little change in its abundance26. In ChIP 
analysis with anti-H3K9me2 antibody, greater decreases in H3K9me2 at the “cc” and “ee” 
region were observed in the inhibitor pre-treated TL cells compared with those under NL 
(Supplementary Fig. 4e). Similar results were obtained from Raw264.7 cells with G9a 
knock-down (Supplementary Fig. 4f), thus up-regulation of the methylation activity of G9a 
correlates with the gene-specific increase in H3K9me2.
ChaC enriches active G9a and its phenotypic associators
Our ChaC design is based on the fact that UNC0638 specifically binds to the enzymatically 
active form of G9a26, aiming to profile the inflammation-phenotypic G9a-interacting 
proteins within chromatin of differently inflamed macrophages. Meanwhile, incorporation of 
amino acid-coded mass tagging (AACT) as in-spectra markers in MS-based quantitative 
analysis29, 30 distinguished protein constituents in the G9a complexes pulled-down by 
UNC0638 respectively from primary BMDMs under different inflammatory states. First we 
synthesized a UNC0638 derivative, UNC2249, with an aminopropyl linker for coupling 
UNC0638 to Sepharose beads that retained the same high affinity to G9a as UNC0638 
(Supplementary Fig. 5 and Supplementary Methods). As illustrated by Fig. 1a, we incubated 
the UNC0638 beads with nuclear extract from equal amounts of BMDMs under either N 
(13C-Arg/Lys-labeled, medium), or NL (13C15N-Arg/Lys, heavy), or TL (unlabeled, light). 
While the level of G9a showed a slight decrease in TL cells compared with that in NL 
macrophages, significantly more G9a was pulled-down by UNC2249 from TL cells than 
from equal amounts of NL cells, indicating higher amounts of chronic-active G9a within the 
silenced chromatin under ET (Fig. 1b). The pull-down proteins from each inflammatory 
state were mixed in equal proportion based on total protein mass and subjected to nanoLC-
MS/MS analysis. In two biological replicates, 2021 proteins were quantified under NL or TL 
compared with their abundances in N cells; the ratios of NL/N and TL/N respectively 
Liu et al. Page 4













represent the relative binding strengths of the corresponding proteins to G9a in either NL or 
TL compared with binding strength in non-stimulated cells (Supplementary Data 1). Thus, 
G9a was found to interact with different proteins, or the same proteins with different binding 
strengths, based on the inflammation-phenotypic methylation activity of G9a in 
differentially inflamed macrophages (Fig. 1c).
We then investigated the quantitative threshold that distinguishes ET-specific G9a-
associating proteins. First, log2(TL/N) or log2(NL/N) of G9a was found at 1.58 or -0.52 
respectively, which was a similar trend with the inflammation-phenotypic changes in the 
methylation activity of G9a (Supplementary Fig. 4e, 4f). Second, based on the ratios for 
multiple proteins known to co-exist with G9a in various complexes, such as HP110, GLP, 
HDAC1, HDAC2, LSD1/KDM1A, WIZ, SIN3A, and Brg1, the threshold to distinguish TL-
specific G9a interactors was empirically determined as the borderline ratios with log2(TL/N) 
> 0.82 and log2(NL/N) < 0.68 or log2(TL/NL) > 1 (Fig. 1c, supplementary Fig. 6, 7), i.e, the 
associations between G9a and these proteins are enhanced specifically in TL cells but 
weakened or non-specific under NL. Notably, in contrast to the relatively poor-correlated 
ratios of NL/N for the proteins quantified by biological replicates, the TL/N ratios of these 
proteins showed good reproducibility with correlation of linearity (R value at 0.82) 
(Supplementary Fig. 8a).
To validate the physiological accuracy of ChaC-identified proteins, we examined whether 
their recruitment onto T-gene promoters is truly dependent upon chronic-active G9a. We 
generated paired Raw264.7 cell lines with either stable shRNA-mediated G9a knock-down 
(KD) or its wild-type counterpart Raw264.7 cells transfected with the empty vector (EV) 
(Supplementary Fig. 9a), from which the results are compared with the UNC0638-treated 
primary BMDMs under defined inflammatory conditions. First, given that HDAC1 is a 
shared component of multiple complexes pulled-down with G9a specifically during ET, we 
examined by ChIP-PCR the inflammation-phenotypic binding of HDAC1 to a T-gene (IL6) 
promoter. Compared with wild-type Raw264.7 cells under NL, IL6-specific binding of 
HDAC1 was increased during ET, which was then diminished in either G9a-KD cells or 
UNC0638-treated BMDMs (Fig. 2a). Thus, the ET-specific recruitment of HDAC1 at the T-
class promoter is dependent upon chronic-active G9a. Conversely, recruitment of G9a was 
affected by HDAC, as the abundance of G9a was reduced within the T-class promoters in 
the TL cells pre-treated by the HDAC inhibitor SAHA (Fig. 2b), implying a coordinated 
action between both histone-modifying enzymes when HDAC removes the acetyl group at 
H3K9 to facilitate accessibility of G9a. Meanwhile, SirT-1, a substrate of G9a18, that plays a 
deacetylation role during ET31, 32, was also quantified as a TL-specific G9a associator (1.1, 
-0.88), and showed a similar enrichment on IL6 as HDAC1, indicating both play the 
redundant role in K9 de-acetylation (Supplementary Fig. 9c). Previous work showed the 
LPS-induced recruitment of Brg1, a key component of chromatin remodeling complex, on 
T-genes was attenuated under TL7. However, in the G9a-depleted cells, recruitment of Brg1 
was recovered on the IL6 distal promoter region, indicating that G9a plays a crucial role in 
determining Brg1 occupation within the T-gene chromatin while G9a co-exists with Brg1 in 
the SWI/SNF complexes (Fig. 2c). Notably, the consistent observations in G9a KD 
Raw264.7 cells versus UNC0638-treated BMDMs demonstrated the high specificity of 
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UNC0638 in binding to the chronic-active G9a that coordinates assembly of a repressome 
within the silenced, LPS-tolerant chromatin.
Chronic-active G9a is at the core of a repressome complex
Meeting the quantitative criteria above, 606 proteins were identified as TL-specific G9a 
interactors, which are predominantly clustered in functions such as DNA methylation, 
mRNA processing, transcriptional repression, and macromolecule metabolism 
(Supplementary Fig. 8c). Further, by using STRING to explore the protein-protein 
interaction network, among these TL-specific G9a-interacting proteins, a few functional 
clusters that contain the intensive interactions were identified, indicating these canonical 
pathways/programs are interactive during ET (Fig. 1d). We also identified multiple factors 
previously known as components of CoREST complex13, CtBP complex14, SWI/SNF 
chromatin remodeling complexes (CRCs)15, and NuRD complex16. For example, HDAC2, 
LSD1, Brg1, SIN3A, and G9a (Fig. 1c) are the known components of CoREST complex, a 
transcriptional repressor module13. Simultaneously, a few proteins associated with 
carbohydrate metabolic processes, such as GRP78 and UGGG1, were identified, consistent 
with that CtBP is a NADH-dependent transcriptional repressor that links carbohydrate 
metabolism to epigenetic regulation by recruiting diverse histone-modifying complexes33. 
Further, we identified WIZ, a known substrate of G9a, which links the G9a/GLP 
heteromeric complex to the CtBP co-repressor machinery34. Accordingly ChIP-PCR 
validated that recruitment of CtBP2 within the T-class promoter was G9a-dependent during 
ET (Fig. 2d). In the same pull-down complexome (Supplementary Data 1), multiple 
components/subunits of ATP-dependent CRCs and NuRD, were found to interact with 
chronic-active G9a. Given that the G9a-mediated methylation of MTA1, a key component 
of NuRD, is required for repression by NuRD35, we also employed ChIP-PCR to investigate 
the G9a-dependent recruitment of the NuRD complex during ET and observed that the 
enhanced TL-specific binding of MTA1 to T-class genes was diminished in either G9a-KD 
Raw cells or UNC0638-treated BMDMs (Fig. 2e), indicating the chronic-active G9a 
determines the stability of a functional NuRD repressor complex within T-chromatin.
To partly explore the functional implication of the TL-specific G9a interactions, we 
compared the dataset of UNC2249/UNC0638 pull-down proteins from TL BMDMs with the 
documented list of G9a non-histone substrates. 8 out of 16 proteins, including ACINUS, C/
EBPt and WIZ that were the known G9a substrates, were found in the UNC2249 pull-down 
complex (Supplementary Table 1). Further, the TL-specific interactome constructed based 
on the UNC2249 pull-down data showed significant overlap with what was mapped based 
on the G9a-target Kme proteome18, 36(Supplementary Fig. 8d), indicating that these proteins 
are the inflammation-phenotypic substrates of chronic-active G9a. Notably, although 
UNC0638 is a G9a substrate-competitive inhibitor, certain G9a substrates were pulled down 
probably due to their roles as the cofactors associating with other proteins that directly 
interact with the enzymatically active G9a, implicating that chronic-active G9a broadly 
facilitates the TL-specific complex assembly by modulating Kme-dependent protein-protein 
interactions. Meanwhile, many proteins previously unknown to associate with G9a were 
identified during ET, generating multiple hypotheses that extend current knowledge of the 
mechanisms involved in the transcriptional regulation of endotoxin tolerance.
Liu et al. Page 6













Chronic-active G9a interacts with select HMTases during ET
For the first time, ChaC revealed an enhanced association between the H3K36-targeting 
HMTase NSD3 and G9a specifically in ET cells (Fig. 1c), which was validated by an in 
vitro co-immunoprecipitation experiment (Fig. 3a), implicating the cooperative action of 
both HMTases during ET. Further, to clarify whether the H3K36-targeting methylation 
activity of NSD3 depends on chronic-active G9a, we compared the abundance of 
dimethylated H3K36 in either paired wild-type vs. G9a-KD Raw264.7 macrophages or non-
treated vs. UNC0638-treated BMDMs. Compared with its TL-specific increase in wild-type 
cells, the level of H3K36me2 decreased in either G9a-KD or UNC0638-treated cells (Fig. 
3b), indicating that both the methylation activity of NSD3 and the deposition of the K36me2 
code on H3 are G9a-dependent during ET. Notably, the methylated level of H3K27 was also 
reduced in G9a-KD or UNC0638-treated cells in line with a report that G9a also targets 
H3K2737. Additionally, the TL-specific enrichment of NSD3 at the IL6 promoter was found 
dependent upon chronic-active G9a (Fig. 3c), revealing that chronic-active G9a also 
coordinates the combinatorial deposition of multiple Kme codes on H3 by recruiting NSD3 
into T-chromatin. Further, a recent report indicated that both NSD3 and G9a participate in 
LSD2 complex for regulating transcription elongation by modulating intragenic 
H3K4me238, supporting our findings of the co-existence of both G9a and NSD3 in the TL-
specific complexome. Meanwhile, ASH2l, another HMTase that catalyzes H3K4 tri-
methylation for transcriptional activation and is also a core member of the transcription-
initiating COMPASS/COMPASS-like complexes39, was identified along with other 
members of COMPASS, WDR82 and CXXC1 (Supplementary Table 2). The enhanced 
interaction between G9a and ASH2l in ET macrophages was also validated by co-
transfection and co-IP experiments (Fig. 3d). Further, even in the LPS-tolerant macrophages, 
G9a showed a higher affinity to the peptide containing H3K4me2 than to its unmodified 
counterpart, while the H3K4me2/3 level was little changed across all inflammatory 
conditions (Fig. 3e). Thus, following acute stimulation G9a may become chronically active 
by first docking on ASH2l-target H3K4me3 deposited in the transcriptional-active 
chromatin associated with T-genes.
Chronic-active G9a promotes gene-specific co-repression
From the silenced chromatin of LPS-tolerized BMDMs, we also found that UNC2249/
UNC0638 selectively enriched/pulled-down a cluster of low-abundance transcriptional 
factors (TFs) or DNA-binding proteins,(Supplementary Table 3). Notably, both 
transcriptional repressive subunits of the NF-κB family, RelB and C-Rel were identified 
specifically in the chronic-active G9a complexome, while other NF-κB subunits including 
p65 and p100/p105 were identified with random, lower TL/N (Supplementary Table 4). 
Meanwhile, ChIP experiments showed NL-specific recruitment of p65 to T-genes 
(Supplementary Fig. 10), indicating dissociation of the inflammation-activating NF-κB 
subunit(s) from the silenced T-gene chromatin, while repressive NF-κB was selectively 
recruited into the TL-specific complexome. Additionally, a transcriptional repressor 
YinYang1(YY1) that was implicated in mediating transcriptional repression by interacting 
with either CtBP40, or Sin3, or HDACs41, was also identified as a TL-specific complexome 
component. Recent work42 indicated that NF-κB-dependent increased YY1 expression 
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negatively regulates IFNβ production, possibly mediated by C-Rel and RelB. Importantly, 
here, YY1 was found together with these co-repressor complex components or 
transcriptional repressors during ET. Accordingly, existence of YY1 at T-gene (IL6) 
promoters was found dependent upon G9a in ET macrophages (Fig. 2f), indicating that 
chronic-activated G9a facilitates the simultaneous access of select TFs to T-gene promoters 
during ET.
To determine the impact of the co-recruitment of combinatorial TFs with G9a on gene-
specific expression during ET, we conducted AACT-based quantitative proteomics29, 30 on 
paired wild-type and G9a-KD Raw264.7 macrophages under TL to identify/profile the 
global, differential proteome expression caused by G9a depletion. In LPS-tolerant 
macrophages, 421 out of 5393 quantifiable proteins showed G9a-repressed expression by 
more than 2-fold; statistically over-represented in GO function clusters for immune 
response, apoptosis, and cell proliferation (Supplementary Fig. 9b). By using Ingenuity 
Pathway Analysis we identified a well-connected gene regulatory network among 198 G9a-
repressing proteins that were previously known gene products regulated by either one or 
several of select TFs (Fig. 2g). Importantly, many of these proteins at the network nodes are 
regulated by multiple TFs, indicating that these TFs that are selectively recruited with 
chronic-active G9a work in concert to co-regulate their target genes. These data reveal that 
chronic-active G9a extends its repressive role in the chromatin-associated, gene-specific 
regulation of ET by coordinating the co-regulatory action of select transcriptional repressors.
Chronic-active G9a interacts with interferon-inducible complexes
Strikingly, a cluster of IFN-inducible proteins including interferon(IFN)-inducible protein 
35 (IFI35) and N-myc-interactor (Nmi) was identified as TL-specific, G9a-interacting 
proteins (Fig. 1c). Both the involvement of G9a in IFN signaling43 and H3K9me2 as an 
epigenetic signature of IFN/cytokine signaling44 were suggested. Therefore, we reasoned 
that chronic-active G9a interacts with this cluster of proteins to extend its function in under-
characterized regulatory pathway(s) for gene-specific regulation during ET. Except for that 
its role in the transcription repression mediated by c-Myc oncogene45, the function of IFI35 
in inflammation control is ambiguous. First we found that the expression of IFI35 remained 
LPS-inducible even under ET (Fig. 4a), showing the typical feature of non-tolerizable (NT)-
class genes6. Meanwhile, G9a-IFI35 association was significantly enhanced during ET (Fig. 
4b). Further, the catalytic SET domain of G9a was found directly involved in the ET-
specific G9a-IFI35 interaction (Fig. 4c), suggesting a determining role of G9a methylation 
activity in coordinating the interferon-inducible complex specifically during ET.
Except for c-Myc, other proteins in the complexes of STATs and Myc proteins46 were all 
identified as TL-specific G9a-interacting partners. To test the conjecture that failure to 
detect c-Myc was due to its high-turnover rate, we examined the in vitro, inflammation-
phenotypic interaction of G9a with c-Myc as well as with other proteins. Consistent with 
TL-specific G9a-c-Myc interaction (Fig. 4d), all four proteins enhanced their association in 
the same complex immunoprecipitated from the LPS-tolerant cells co-transfected with four 
epitope-tagged constructs respectively expressing IFI35, G9a, c-Myc, Nmi (Fig. 4e). 
Further, these associations were promoted by both G9a and H3K9me2, as the complex 
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involving all components was pulled-down only from the co-transfected cells under TL 
using a H3K9me2-containing peptide (Fig. 4f). Thus, both chronic-active G9a and 
H3K9me2 are required for the integrity of IFI35/c-Myc/Nmi complex that specifically 
recognizes/docks on H3K9me2 during ET.
We further investigated whether c-Myc impacts the function of G9a during ET by measuring 
the methylation activity of G9a with or without over-expressing c-Myc. We transfected 
epitope-tagged G9a or co-transfected both c-Myc and G9a into the stable TLR4-expressing 
cells under TL. With a H3 N-terminal peptide as the substrate, HMTase activity increased 
with the co-expression of both proteins, indicating that c-Myc is a part of the complex 
involving chronic-active G9a (Fig. 4g). We then investigated the impact of this G9a/K9me2-
dependent complex on NF-κB-dependent transcription. An NF-κB-target luciferase reporter 
was co-transfected with the expression vector(s) of either G9a, or c-Myc, or both. As shown 
in Fig. 4h, LPS-induced NF-κB activity decreased with increasing expression of either G9a 
or c-Myc, while IFI35 and Nmi had little effect on G9a/c-Myc-associated suppression of 
NF-κB activity (Supplemental Fig. 11), indicating that c-Myc and chronic-active G9a work 
synergistically to suppress pro-inflammatory NF-κB activity during ET. Also, this G9a-
dependent suppression of NF-κB activity is readily interpreted by our observation of the 
G9a-dependent existence of RelB, the repressive subunit of NF-κB, in the T-gene 
nucleosome during ET (Supplementary Table 4).
c-Myc regulates G9a-dependent gene-specific transcription
Myc broadly targets more than 1500 genes involving in diverse biological processes47. To 
uncover G9a-dependent, c-Myc-regulated pathways/processes, we performed ChIP-seq 
experiments using anti-c-Myc antibody on paired wild-type and G9a-KD Raw264.7 cells 
under TL. Comparative genome-wide mapping of c-Myc binding loci was obtained to 
identify the G9a-dependent occupancy of select c-Myc-regulated genes (Fig. 5a). G9a 
knock-down led to decreased binding of c-Myc to 1132 genes, including a number of T-
genes such as IL10, Lipg, Itga4 and apoptosis-related genes including Bax and Bcl2l2-
Pabpn1 (Fig. 5b). For instance, the enrichment of c-Myc at the IL10 distal promoter was 
found in wild-type but not in G9a-KD cells. No peak was found in the proximal promoter of 
IL10 in either wild-type or G9a-KD cells, consistent with the results from ChIP-PCR 
validation (Fig. 5c). Notably, 38% of the G9a-depedent, c-Myc binding genes identified by 
ChIP-seq are c-Myc-regulated genes found in fibroblasts and B-lymphoid tumor cells48, 49 
(Supplementary Data 2), indicating that c-Myc also contributes to ET through regulating 
select genes in the G9a-dependent manner. Further, ChIP-qPCR validated the dual-
dependence of other known T-class or NT-class genes. For example, c-Myc showed 
enhanced binding to the loci of IL6 specifically under TL, which was diminished 
consistently in either UNC0638-treated BMDMs or G9a-KD Raw264.7 cells (Fig. 5d). c-
Myc binding to the NT-genes was not affected by either the inhibitor or G9a-KD, all 
demonstrating that the TL-specific recruitment/accessibility of c-Myc to T-gene promoters 
is dependent upon chronic-active G9a. As well, along with additional recruitment of c-Myc 
to IL6, IP-10, and p21 (the universal cell cycle inhibitor p21cip)50 in the wild-type cells 
under TL compared with NL, siRNA-mediated knock-down of G9a or UNC0638 inhibition 
of chronic-active G9a led to reduced c-Myc binding to these genes. Given the pro-
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inflammatory nature of IL6, this result suggested that the G9a-dependent binding of c-Myc 
to T-gene promoters is responsible for the suppression of this class of the genes during ET. 
Further, given that both IP-10 and p21 are known c-Myc-regulated genes involved in cell 
survival, we concluded that chronic-active G9a extends its epigenetic repressive role in cell 
fate decision by regulating the transactivation activity of c-Myc during the inflammation 
control of ET.
Chronic-active G9a inhibits c-Myc degradation during ET
Given our newly characterized, broad effect of c-Myc on transcriptional co-regulation, we 
next investigated how chronic-active G9a regulates c-Myc during ET. We first compared the 
inflammation-phenotypic expression of c-Myc in wild-type versus G9a-KD Raw264.7 cells 
(Fig. 6a). For wild-type cells, compared with its abundance under N or NL, slightly less c-
Myc was observed under TL. Although little change was found for both wild-type and G9a-
KD cells under N or NL, the abundance of c-Myc was substantially lower in the TL G9a-KD 
cells, suggesting the role of chronic-active G9a in maintaining the abundance of c-Myc in 
LPS-tolerant macrophages. We then determined at what levels G9a regulates c-Myc 
stability. First, RT-PCR showed that c-Myc mRNA was elevated in G9a-depleted cells, 
suggesting that G9a suppresses c-Myc transcription (Fig. 6b). Second, the rate of c-Myc 
decay following inhibition of protein synthesis with cycloheximide (CHX) was about four 
times slower in the TL wild-type cells than in the G9a KD counterpart (Fig. 6c). Also, more 
c-Myc was detected with increasing expression of G9a (Supplementary Fig. 12a and 12b), 
indicating that chronic-active G9a stabilizes c-Myc at T-gene promoters by inhibiting c-Myc 
degradation during ET. Further, we respectively pre-treated either wild-type or G9a-KD 
cells with the proteasome inhibitor MG-132, which allowed analysis of the time-dependent 
translation of c-Myc mRNA when protein degradation was blocked. In contrast to the time-
dependent, progressive accumulation of c-Myc in G9a-KD cells, the MG-132-induced c-
Myc was actually reduced with a longer post-treatment time in the presence of G9a (Fig. 
6d), indicating that G9a also attenuates c-Myc translation, consistent with the TL-specific 
decrease of c-Myc in the wild-type cells (Fig. 6a). Thus, G9a-dependent inhibition of c-Myc 
degradation at the post-translational level is the predominate process that determines the 
stability and then the accessibility of c-Myc onto T-gene promoters.
G9a suppresses cell response and gene-specific secretion
To further clarify the impact of G9a-mediated stabilization of c-Myc on cell fate decision 
during ET, we pre-treated wild-type and G9a-KD cells with UNC0638 and chronically 
stimulated them with LPS. While little effect of UNC0638 treatment was observed for the 
non-treated wild-type cells, the relatively high percentage of survived cells under TL was 
reduced in cells pre-treated with UNC0638 (Fig. 6e). Thus, UNC0638 could re-sensitize ET 
macrophages and promote their apoptosis by inhibiting chronic-active G9a, revealing that c-
Myc plays a cooperative role with TL-specific G9a complexome, the IFN signaling cluster 
in particular, in regulating endotoxin tolerance.
We further investigated the impact of chronic-active G9a on gene-specific transcription and 
translation. First, we employed a label-free quantitative proteomic method for profiling 
BMDM secretome51 to identify the proteins differentially secreted from the BMDMs under 
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N, NL, TL without or with UNC0638 treatment respectively. As a result, the secretion levels 
of 45% of a total of 992 identified proteins showing repressed releases was found increasing 
in the UNC0638-pre-treated BMDMs under TL (Supplementary Fig. 13a). RT-PCR analysis 
of some of these T-genes or 18 out of 31 selected genes also showed the similar trend of 
G9a-dependent changes (Supplementary Fig. 13b), all indicating that chronic-active G9a 
broadly affects on the endotoxin-induced transcription and translation of select pro-
inflammatory/T-class genes.
DISCUSSION
Because protein complexes are immunoprecipitated based on the abundance and not the 
activity of the bait protein19, conventional antibody-dependent approaches for interactome 
screening are less sensitive/accurate in distinguishing in situ functional interactions. Here we 
present a breakthrough in introducing an activity-based ChaC methodology to reveal the 
inflammation-phenotypic, functional constituents of the chromatin writer complexome that 
regulates the gene-specific transcription. Unlike most ABPP inhibitors that bind to the active 
site of their target enzymes, our ChaC chemoprobe is a substrate-competitive ligand, so that 
the G9a-scaffolding function to accommodate the functionally relevant protein interactions 
is preserved. Further, because of its high-specificity in binding to active G9a, both antibody 
specificity and cross-activity are no longer the concerns.
Firstly, our characterization of HDAC1, SirT-1, and Brg1 as the TL-specific G9a-
associating partners (Fig. 2c) support the idea that chronic-active G9a holds up particular 
chromatin remodeling complexes within the silenced chromatin, and, in parallel, both 
HDAC114 and SirT-1 are recruited to chromatin and then works in concert with chronic-
active G9a to promote the phenotypic PTM conversion at H3K9 (Supplementary Fig. 1c, 
2a). Secondly, in the TL-specific complexome, G9a interacts with select writer(s) or 
eraser(s) of these methyl-lysine sites, leading to concerted changes of multiple methyl-lysine 
marks (Fig. 3). The constitutive interaction between ASH2l and G9a (Fig. 3d) provided an 
interpretation for the previous finding that G9a targets H3K9 at the euchromatic regions 
demarcated by K4me2/3 where G9a is first recruited to the transcriptional-activated regions 
to later suppress transcription of T-genes11. H3K4me2/3 plays a critical auxiliary role, 
which is maintained by the G9a-ASH2l interaction. Here, our combined results provide a 
systems view that, during ET, chronic-active G9a coordinates deposition of combinatorial 
Kme sites on H3 known to play either an individual or combinatorial role in gene 
suppression52 to synergistically maintain a repressive chromatin landscape at T-gene 
promoters.
In tumor cells, c-Myc is an oncogenic transcriptional activator47 that preferentially targets 
genes enriched with the transcriptional-active codes, such as H3K4me2/3 and H3K9ac, 
through interaction with a variety of histone acetyltransferase (HAT)-associated protein 
complexes where c-Myc is also a substrate of defined HATs and can be stabilized by 
acetylation53. Conversely, little is known about how the transcriptional activity of c-Myc is 
regulated during inflammation control. We are the first to find that, specifically in ET 
macrophages, c-Myc interacts with G9a in an IFI35/c-Myc/Nmi complex that can dock on 
the transcriptional repressive mark of H3K9me2. Multiple c-Myc-regulated genes were also 
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identified in the G9a-dependent co-regulatory network involving a combinatorial set of 
transcriptional repressors, indicating that c-Myc is a major component of the G9a 
repressome (Fig. 2g). Further, given that c-Myc is expressed ubiquitously, and its stability is 
essential for its transcriptional activity, our finding that chronic-active G9a stabilizes c-Myc 
within promoters of select genes implicates the G9a-dependent role of c-Myc in 
transcriptional repression during ET. Therefore, c-Myc is a dual-functional transcriptional 
factor, alternatively acting as either activator or repressor based on its epigenetic 
environment involving interacting histone codes and select histone-modifying enzymes. 
During ET c-Myc becomes a G9a/H3K9me2-dependent transcriptional repressor in a similar 
way as it acts as a HAT/K9ac-dependent transcriptional activator (Fig. 7a). This conclusion 
is also supported by reports that c-Myc plays a regulatory role in anti-inflammatory 
macrophages54 and it interacts with a G9a-associating factor Gfi-1 at the p21-promoter 
region to epigenetically repress p2155, indicating that the epigenetic mechanisms dictate the 
phenotypic binding of Myc to select target genes. Further, global profiling of G9a-regulated 
protein expression together with ChIP-seq to identify the regulatory DNA elements reveal 
select genes showing the dual-dependence on both G9a and c-Myc during the ET phenotype. 
These genes mostly fall into the over-represented functional categories associated with 
immune or inflammatory response, and apoptosis, demonstrating exactly how G9a 
coordinates the gene-specific regulation of chronic inflammation through the methylation-
activity-based complexome assembly.
Previous evidence from independent studies suggests that, in endotoxin-tolerant 
macrophages, nucleosomes are repositioned from permissive to repressive locations, and 
both promoter chromatin remodeling and NF-κB transactivation are disrupted56. Our 
repressome findings now provide the molecular illustration that the specificity of the 
inflammation-phenotypic chromatin reprogramming is controlled by particular transcription 
factors and co-factors that are selectively recruited: during ET, select transcriptional 
repressors including RelB, YY1, c-Myc were first recruited into the T-gene chromatin17, 57 
to replace the transcriptional activators such as RelA/p65 (Fig. 2f), and then interact with the 
chronic-activated G9a which in turn stabilizes the binding of these factors to select classes 
of the genes. This idea is consistent with the previously reported correlation between RelB 
expression and the induction of repressive nucleosome positioning58 as well as the in vitro 
interaction between GST-tagged G9a and RelB during ET17. Meanwhile, the major factor 
complexes associated with chromatin plasticity and mobilization including NuRD and 
SWI/SNF complexes were simultaneously identified in the G9a repressome, indicating that 
chronic-active G9a interacts with these complexes to integrate activities of nucleosome 
positioning, ATP-dependent chromatin remodeling, and transcriptional repressors. Also 
supported by comparative proteomic experiments on paired wild-type and G9a-KD 
macrophages, in which global protein products of G9a-silenced genes were identified, we 
concluded that chronic-active G9a participates in the co-regulation by select transcriptional 
repressors in cross talk that synergistically pronounce the gene-specific repression.
On a systems view we are the first to demonstrate that as the writer of the chromatin 
repressive mark H3K9me2, in a methylation-activity-dependent manner, G9a couples select 
biological pathways/programs across multi-phases of transcription including DNA binding, 
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nucleosome localization, and transcription factor recruitment to the gene-specific epigenetic 
regulation by recruiting specific complexes to the chromatin of T-genes, which 
systematically define a transcriptionally silenced chromatin (Fig. 7b). Technically, our ChaC 
approach can generate activity-based interactome data in a physiologically accurate manner 
and is generically applicable to dissect a variety of phenotypic chromatin architectures in the 
context of a functional protein complexome.
Methods
Reagents and Mice
Lipopolysaccharide (LPS) (Escherichia coli 0111:B4, ultrapure) was purchased from 
InvivoGen (USA, invivogen, cat# tlrl-pelps). HEK 293 stable TLR4-MD2-CD14 cell line 
was also purchased from InvivoGen. All components of cell culture media and protease 
inhibitor cocktails were purchased from Sigma (St, Louis, MO). Fetal bovine serum (FBS) 
was obtained from Gibco (Life Technologies). Trypsin was purchased from Promega 
(Madison, WI). All chemicals were either sequence- or HPLC- grade unless specifically 
indicated. Antibodies against G9a cat# 07-551 (1:1000), H3K9me2 #07-441 (1:1000), 
H3K4me3 #07-473 (1:1000), H3K4me2K9me2 #07-1843 (1:2000) were purchased from 
Millipore. Antibodies for c-Myc (N-262) #sc-764x (1:2000), Brg1 (H-88) #sc-10768x 
(1:2000), HDAC1 #sc-7872 (1:1000), MTA1 #sc-373765 (1:1000), YY1 (H-414) #sc-1703 
(1:1000), SIRT1 #sc-15404 (1:1000), β-ACTIN #sc-1616 (1:2000) were from Santa Cruz. 
Antibodies for H3 #ab1791 (1:5000), γ-tubulin #ab11316 (1:5000) were from Abcam. 
Antibody for H3K36me2 #39255 (1:5000), H3K27me3 #39156 (1:5000) were purchased 
from Active Motif; for H3K27me2 #PA5-17376 (1:2000) was from PIERCE; for p-p65 
(S536) #3033 (1:1000) was from Cell Signaling; for NSD3 #GTX109396 (1:1000) was from 
GeneTex; CtBP2 #612044 (1:2000) was from BD Biosciences. Anti-HA (clone HA-7) 
(1:4000) and anti-flag M2 (clone M2) (1:4000) antibodies were from Sigma. Six to eight 
week-old male or female mice (C57BL/6 strain) were used. All mouse procedures in this 
study were approved by the Institutional Animal Care & Use Committee (IACUC) at 
University of North Carolina at Chapel Hill. Uncropped immunoblots are provided in 
Supplementary Fig. 14.
BMDM culturing and AACT/SILAC labeling
Bone marrow progenitors were rinsed out from femur and tibia bones of C57BL/6 wild-type 
mice. Red blood cells were removed by ACK Lysing Buffer (Gibco). Bone marrow cells 
were cultured on Petri dishes for 6 days in the DMEM supplemented with 10% FBS, 20% 
L929-conditioned media (LCM), either regular or AACT-containing media. On day 7, 
BMDMs were lifted with cold TEN buffer (40mM Tris-HCl pH7.4, 1mM EDTA, 150mM 
NaCl) and re-plated on tissue-culture treated plates. Stable isotope labeling growth media 
were prepared7. Briefly, the growth media in depletion of lysine and arginine were 
supplemented with either 13C6-lysine (K6)/13C6-arginine (R6) or 13C615N2-arginine 
(K8)/13C615N4-arginine (R10) respectively (Sigma-Aldrich cat#643459, cat#643440, 
cat#608041, cat#608033). Primary BMDMs or Raw264.7 cells were either left unstimulated 
(‘N’), or subjected to a single LPS stimulation at 1μg/ml, or first primed with 100ng/ml LPS 
to induce endotoxin tolerance for 24 hours (‘T’), followed by the second LPS challenge at 
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1μg/ml (‘TL’). Cells were grown at 37°C in a humidified atmosphere and 5% carbon dioxide 
in air.
Histone sample preparation
Core histone proteins were prepared by Histone Purification Mini Kit (Active Motif 
cat#40026). Briefly, adhered cells were washed with pre-warmed serum-free media twice 
and were then harvested. The pellet was lysed with 1.5ml extraction buffer per 2×107 cells 
and homogenized by repetitive pipetting. The cell lysate was processed under agitation for 2 
hours at 4°C before the crude histone was clarified, neutralized and loaded onto the column. 
Histone proteins were purified by a C8 column and were precipitated by 4% perchloric acid 
according to the manufacturer’s instructions and were resolved in HPLC water. All steps 
were processed on ice or in cold room, for the maximum preservation of histone 
modifications.
HPLC purification of histone and top-down mass spectrometry
Histone proteins were injected onto a C-8 column with a particle size of 7μm and the inner 
diameter of 2.1mm (Perkin Elmer cat# 07110060) using an Agilent 1100 series RP-HPLC 
(Agilent, Santa Clara CA). The core histone proteins were separated using the gradient: 
35%–60% Acetonitrile/0.1%TFA for 75 minutes. Protein elution was monitored by UV 
absorption at the wavelength of 214nm. Histone fractions were collected, lyophilized, and 
then subjected to μESI-FTICR-MS analysis59.
We also explored the use of a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, 
San Jose, CA) to perform top-down MS analysis of inflammation-phenotypic HPLC-
purified, full-length H3.1 (The methodology innovation will be reported elsewhere). Briefly, 
mass analysis was achieved in both Full-MS, single ion monitoring (SIM) of +19 charge 
state, and electron transfer dissociation-tandem mass spectrometry (ETD-MS/MS) modes60 
with instrument resolution setting of 120,000 at m/z 400 Da. All samples were dissolved in 
solution of 50:50 methanol:water 1% formic acid and introduced to the mass spectrometer 
via direct infusion at a flow of 8 μL/min. ETD was performed specifically on the isotopic 
clusters of two peaks (average m/z of 809.29 Th and m/z of 810. 03 Th) for the +19 charge 
state that correspond to various isoforms showing abundance variations respectively under 
N, NL, and TL states. The lower m/z range: 200-780 Th product ions were processed 
manually in all ETD-MS/MS spectra by assigning sequence ions to theoretical masses 
corresponding to a diverse set of combinatorial PTMs61 that includes R2(me2), R2(me), 
K4(ac), K4(me2), K4(me), K9(ac), K9(me2), K9(me), K9(me3), K14(ac), K14(me), 
K14(me2), K27(ac), K27(me), K27(me2), K36(ac), K36(me), K36(me2).
Nuclear extraction
Nuclear extract was prepared62. Briefly, BMDM cells were collected and re-suspended in 
hypotonic buffer A (10mM HEPES pH7.9, 1.5mM MgCl2, 10mM KCl, 1mM PMSF, 1mM 
DTT and protease inhibitor cocktail). After incubating for 10min on ice, the swollen cell 
pellet was spun down and re-suspended in two volumes of Buffer A and homogenized to 
release cytosolic fraction. Nuclei were collected by centrifugation at 14000rpm for 10min, 
and homogenized with 10 strokes in Buffer C (20mM HEPES pH7.9, 1.5mM MgCl2, 
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0.2mM EDTA, 420mM NaCl, 25% Glycerol, 1mM PMSF, 1mM DTT and protease 
inhibitor cocktail). Extraction was allowed to proceed under agitation for 30 min at 4 °C 
before the nuclear extract was clarified by centrifugation at 14000rpm for 30 min at 4 °C. 
The extract was dialyzed overnight to 50 volumes buffer D (20mM HEPES pH7.9, 0.2mM 
EDTA, 100mM KCl, 20% Glycerol, 1mM PMSF, 1mM DTT and protease inhibitor 
cocktail). Adding Triton X-100 to a final concentration of 0.1% and centrifuging again, the 
supernatant was the nuclear extract.
Chromatin activity based chemoproteomics
An amino propyl linker was added for coupling UNC063826 to ECH sepharose 4B beads 
(General Electric cat# 17-0571-01). UNC0638 immobilized on sepharose beads were 
washed in Buffer D with 0.1% Triton-X100 twice before added into the nuclear extract. 
After incubation overnight, the beads was washed with 250mM KCl buffer (20mM HEPES 
pH7.9, 0.2mM EDTA, 250mM KCl, 20% Glycerol, 1mM PMSF, 1mM DTT and protease 
inhibitor cocktail) for five times. The pull-down products were eluted by boiling the beads in 
2×SDS-PAGE loading buffer for 10 minutes. For histone peptide pull-down experiments, 
histone H3 N-tail peptides was synthesized with a biotin tag, then the peptide was 
conjugated to streptavidin beads and the pull-down experiment was carried out in a similar 
way as UNC0638 pull-down except for that the washing buffer was substituted by a low-
stringent buffer containing 100mM KCl. The pull-down products were resolved by SDS-
PAGE, either for immunoblotting or followed by in-gel tryptic digestion prior to MS 
analysis.
Stable shRNA-mediated knockdown of G9a
The lentiviral plasmids for the shRNA targeting mouse Ehmt2 (G9a) in a vector pLKO.1 
were purchased from Thermo Scientific Open Biosystems. The shRNA-Ehmt2 target 
sequence is TTGTTATCTAAATCGAAGAGG. A pLKO.1 empty vector (EV) without 
shRNA sequence was used as the wild-type control. To generate virus, pLKO.1-shRNA 
plasmids were co-transfected into 293T cells with ViraPower Mix (Invitrogen) by 
jetPRIME™ in vitro DNA & siRNA transfection reagent (Polyplus). Viral supernatants were 
collected 24 and 48 hours following transfection and were used to transduce Raw264.7 cells 
by spinoculation. Forty-eight hours after the transfection, 8μg/ml puromycin was added to 
initially select puromycin-resistant clones. The stable clones were maintained in the media 
containing 4 μg/ml puromycin. The level of G9a expression was examined for individual 
clones. Those clones with at least 90% knockdown efficiency were used in the experiments.
Quantitative proteomic profiling protein expression during ET
The pair of Raw264.7 cell lines either stably expressing shRNA for G9a KD, or the wild-
type with empty vector (EV) were cultured for AACT labeling as described above. Both sets 
of the cells were primed with a low-dose LPS at 100ng/ml for 24 hours and then challenged 
with a high-dose LPS at 1μg/ml to introduce endotoxin tolerance. Cells were harvested 2 
hours after LPS challenge and lysed in the buffer containing 8M Urea, 50mM Tris-HCl 
pH8.0, 75mM NaCl, 1mM MgCl2, 500 units Benzonase, and protease inhibitor cocktail. 
Equal amounts (0.5 mg) of the lysate from each pool were mixed. The mixed protein pool 
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was first reduced with DTT followed by cysteine alkylation with iodoacetamide, and then 
diluted 4-fold by 25mM Tris-HCl pH8.0, 1mM CaCl2. The diluted protein mixture was 
digested with trypsin (Promega #V5113) at 37°C overnight and then replenished trypsin to 
further digestion for another 6 hours. The peptides were desalted on Sep-Pak Light C18 
cartridge (Waters, Milford, MA) and dried. The peptides were dissolved in 10mM 
ammonium formate pH10.0, and subjected to high-pH RPLC separation performed with an 
Xbridge C18, 250×4.6mm column containing 5 μM particles and equipped with a 
20×4.6mm guard column (Waters, Milford, MA). The mobile-phase A was consisted of 
10mM ammonium formate pH10.0 and B 10mM ammonium formate pH10.0 with 90% 
Acetonitrile. Peptide separation was accomplished using the following gradient: from 0 to 
5% B in 5 min, from 5 to 35% B in 30 min, from 35 to 70% B in 7.5 min, and held at 70% B 
for an additional 5 min. Sixty fractions were collected and concatenated into 30 fractions by 
combining fractions 1, 21, 41; 2, 22, 42. The samples were dried and desalted on StageTip 
containing 4×1mm C18 extraction disk (3M).
Mass spectrometry analysis of ChaC pull-down products
Peptide samples were dissolved in 0.1% formic acid and subjected to nanoLC-MS/MS 
analysis by using an online nanoLC ultra2D system (Eksigent) coupled to an LTQ Orbitrap 
Velos mass spectrometer (Thermo Scientific, San Jose, CA)7. Briefly, LC-MS experiments 
were performed in a data-dependent mode with Full-MS (externally calibrated to a mass 
accuracy of < 5 ppm, and a resolution of 60 000 at m/z 400) followed by CID MS/MS of the 
top 10 most intense ions. Mass spectra processing and peptide identification were performed 
on the Andromeda search engine in MaxQuant software (Ver. 1.2.0.18) 63 against a mouse 
Uniprot database. All searches were carried out with cysteine carbamidomethylation as a 
fixed modification, while methionine oxidation and protein N-terminal acetylation as 
dynamic modifications. Peptides were confidently identified using a target-decoy approach 
with a peptide false-discovery-rate (FDR) of 1% and a protein FDR of 1%. Data processing 
and statistical analysis were performed on Perseus (Ver. 1.2.0.17) 64. AACT/SILAC 
quantitation (3-plex K0R0, K6R6, K8R10, or 2-plex K0R0, K8R10) analysis was carried out 
similarly as previous described 7. The AACT ratios of the proteins were derived from the 
comparison of the extracted ion chromatogram peak areas of all matched light (L) peptides 
with those of the medium (M) or heavy (H) peptides. The ratios of M/L or H/L were also 
verified by visual inspection of the raw mass spectra.
Biological processes are categorized by DAVID (http://david.abcc.ncifcrf.gov/). Protein-
protein interaction network analysis was performed by an online bioinformatics tool 
STRING (http://string-db.org). Transcriptional factor regulatory network was preceded by 
IPA (Ingenuity pathway analysis)
RNA preparation and quantitative PCR
Total RNA was isolated using RNeasy kit (Qiagen). First-strand cDNA was synthesized by 
M-MLV reverse transcriptase (Promega, car# M170B) and diluted 10 times for quantitative 
PCR. Real-time PCR was performed using SYBR Green Master Mix (Thermo Fisher, cat# 
0221). All measurements were normalized to GAPDH and represented as relative ratios. 
PCR primers for real-time PCR are summarized in supplementary table 5.
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Sample collection of the macrophage secretome
Primary BMDM cells were primed with 250nM UNC0638 or DMSO respectively for 16 
hours. Cells were then either left unstimulated (‘N’), or subjected to a single LPS challenge 
at 500ng/ml for indicated hours (‘NL’), or first primed with 100ng/ml LPS to induce the 
endotoxin tolerance for 24 hours, followed by the second LPS challenge at 500ng/ml for 
indicated hours (‘TL’). Prior to the LPS challenge, cells were washed once, and culture in 
serum-free DMEM without phenolred, containing 1mM sodium pyruvate and 10mM L-
glutamine. The secreted proteins were harvested and prepared51.
Label-free quantitative analysis of macrophage secretome
LFQ secretome analyses were performed via reversed phase LC-MS/MS using a Proxeon 
1000 nano LC system coupled to an Q Exactive mass spectrometer (Thermo Scientific, San 
Jose, CA). The Proxeon system was configured to trap peptides using a 3 cm long 100 μm 
i.d. C18 column at 5 uL/min liquid flow that was diverted from the analytical column via a 
vent valve while elution was performed by switching the valve to make the trap column in-
line with a 15 cm long, 75 μm i.d., 3.5 μm, 300Å particle; C18 analytical column. Analytical 
separation of all the tryptic peptides was achieved with a linear gradient of 2–35% buffer B 
over either 240 min at a 300 nL/min flow rate, where buffer A is aqueous solution of 0.1% 
formic acid and buffer B is a solution of acetonitrile in 0.1% formic acid.
LC-MS experiments were also performed on a in a data-dependent mode with Full-MS 
(externally calibrated to a mass accuracy of < 5 ppm, and a resolution of 70 000 at m/z 200) 
followed by HCD-MS/MS of the top 20 most intense ions. High-energy-collision-activated 
dissociation (HCD)-MS/MS was used to dissociate peptides at normalized collision energy 
of 27 eV in the presence of nitrogen bath gas atoms. All secretome samples consisting of 
three biological replicates were subjected to single-shot independent LC-MS runs resulting 
in the production of 48 LC-MS runs for global peptide analysis. Mass spectra were 
processed, and peptide identification was performed using Andromeda search engine found 
in MaxQuant software ver. 2.2.1. (Max Planck Institute, Germany) All protein database 
searches were performed against the uniprot mouse protein sequence database. Peptides 
were identified with a target-decoy approach using a combined database consisting of 
reverse protein sequences uniprot mouse sequence and common repository of adventitious 
proteins (cRAP). The cRAP database was obtained from the Global Proteome Machine 
(GPM) ftp site (ftp://ftp.thegpm.org/fasta/cRAP). Peptide identification was made with a 
false discovery rate (FDR) of 1% while peptides were assigned to proteins with a protein 
FDR of 5%. A precursor ion mass tolerance of 20 ppm was used for the first search that 
allowed for m/z retention time recalibration of precursor ions that were then subjected to a 
main search using a precursor ion mass tolerance of 5 ppm and a product ion mass tolerance 
0.5 Da. Search parameters included up to two missed cleavages at KR on the sequence, and 
oxidation of methionine as a dynamic modification. All and protein and peptide 
identifications are reported by filtering for reverse and contaminant proteins.
Label-free quantitation was based on peak area65–67. The measured area under the curve 
(AUC) of m/z and retention time aligned extracted ion chromatogram (XIC) of a peptide 
was performed via the label-free quantitation module found in MaxQuant [ver. 1.3.0.5].65 
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All replicates (biological and technical replicates) of each experimental conditions: N, 
NL-16hrs, TL-16hrs, were included in the LFQ experimental design with protein-level 
quantitation and normalization performed using unique and razor peptide features 
corresponding to identifications filtered with a peptide FDR of 0.01, and protein FDR of 
0.05. The MaxQuant protein groups and evidence files were processed using the statistical 
analysis and visualization features found in Perseus [ver. 1.4.1.3] (Max Planck Institute, 
Germany)
Tagged Immunoprecipitation
HEK 293 stable TLR4-MD2-CD14 cell line (Invivogen) was transfected with indicated 
constructs by jetPRIME™ transfection reagent (Polyplus, cat#114-15). The cells were 
harvested from indicated conditions, and lysed with RIPA buffer containing 20mM Tris-
HCl, 137mM NaCl, 2mM EDTA, 10% glycerol, 0.5% NP-40 and 1mM PMSF. Cell lysates 
were incubated with affinity beads for overnight at 4°C on rotator. Affinity beads were 
washed with RIPA buffer four times before subjected to immunoblot assay.
Chromatin Immunoprecipitation
ChIP experiments for studying histone modifiers and transcriptional factors were carried out 
in dual cross-linking way 68 with minor modifications. Cells were fixed by 2mM DSG 
(disuccinimidyl glutarate, ProteomChem #c1104) for 45 min. 1% (v/v) formaldehyde was 
then added and incubated for 15 min. Cross-linking reactions were quenched by adding 
glycine to 0.1M, followed by PBS washing. Cells were scraped, and nuclei were pelleted by 
0.5% NP-40 lysis buffer (50mM pH8.0 Tris-HCl, 85mM KCl, 0.5% NP-40). The nuclear 
fraction was extracted with RIPA buffer (50mM pH8.0 Tris-HCl, 150mM NaCl, 1mM 
EDTA, 1% Triton-x100, 0.1% SDS, 0.1% sodium deoxycholate) and sonicated to 200–
1000bp DNA fragments, then incubated overnight with the antibody. The antibody 
complexes were linked to protein A/salmon sperm DNA beads (Cell signaling, cat #9007) 
and washed thoroughly. The complexes were then eluted from the beads by 1% SDS, and 
incubated with NaCl to reverse the cross-linked products. Afterwards, proteins were 
digested by protease-K and the released DNA was purified by QIAquick PCR purification 
Kit (QIAGEN, cat #28104), and processed to quantitative PCR assay. ChIP experiments for 
studying histone post-translational modifications were started from a one-step fixation of 1% 
(v/v) formaldehyde for 10 min, followed by the same steps as dual crosslinking ChIP 
described above. PCR primers for real-time PCR are summarized in supplementary table 6.
ChIP-seq
ChIP experiments against c-Myc antibody (Santa Cruz cat#sc-764x) were processed in G9a 
KD stable cell line and wild-type control Raw264.7 cells respectively following the one-step 
formaldehyde fixation procedure. ChIP’s DNA from two cell lines and INPUT from wild-
type cells were subjected to library construction using ThruPLEX™-FD Prep Kit 
(RUBICON GENOMICS, cat# R40012-0 8). DNA libraries are cleaned up with Agencourt 
AMPure XP beads (Beckman Coulter cat# A63880), quantified by Qubit 2.0 fluoremeter 
and qualified by Experion™ automated electrophoresis system (BIO-RAD). Three libraries 
were pooled and subjected to deep sequencing on Illumina Hiseq 2000. ChIP-seq data were 
aligned using Bowtie 2 (Version 2.1.0)69 to build version NCBI37/mm9 of mouse genome. 
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ChIP-seq enriched region over INPUT background were identified with peaking finding 
algorithm of MACS70 (Model based analysis of ChIP-seq).
G9a activity assay
293/TLR4-MD2-CD14 Cells were transfected with tagged-G9a plasmids and tagged-c-Myc 
plasmids as indicated. The next day, transfected cells were primed with 100ng/ml LPS for 
24 hours and then challenged with 1μg/ml LPS for another 45 minutes. Cells were harvested 
and subjected to tagged IP with anti-flag affinity beads. After overnight incubation, anti-flag 
beads were washed with reaction buffer (Tris-HCl 20mM pH8.0, 25mM NaCl, 0.025% 
Tween-20 and 1mM DTT). In vitro assay was carried out as previous described 26. Briefly, 
anti-flag beads were incubated with 5μM S-adenosyl-methionine (SAM) and 2nM 
fluorescent labeled H3 N tail peptides (ARTK4(me)QTARK9STGGK14-(5-FAM)) in 
reaction buffer. After incubation for 2 hours at 25°C, 40 pg/μl endoproteinase-LysC (Endo-
LysC) was added and allowed to digest the remaining unmethylated substrate peptides for 1 
hour prior to separation on the Caliper LabChIP EZ Reader II (Caliper Life Sciences, 
Hopkinton, MA). The histone H3 lysine 9 methyltransferase activity was represented as the 
percentile of peptide substrate being methylated. Recombinant G9a was applied as positive 
control. The reactions lacking catalytic enzyme or methyl donor SAM were applied as 
negative controls.
NF-κB reporter assay
293/TLR4-MD2-CD14 Cells were seeded on 24-well plates one day before transfection so 
that they will be 90% confluent at the time of transfection. The next day, cells were 
transfected with 225ng pGL2-ELAM promoter Firefly luciferase transgene plasmid and 
450ng plasmids indicated. The pRL-TK plasmid, which expresses Renilla luciferase, was 
transfected into cells at 75ng as an internal control to normalize transfection efficiency and 
sample handling. The cells were stimulated with 1μg/ml LPS for 6 hours before harvesting. 
The activities of the two kinds of luciferase were measured with their respective substrates 
with a dual luciferase assay kit (Promega). The luminescence reads reflecting NF-κB 
activity were obtained from the division of Firefly luciferase reads by Renilla luciferase 
reads. The data represented in the corresponding figures were the luminescence normalized 
to the control sample transfected with empty vector instead of functional plasmids. Y axis 
indicates relative NF-κB activity. The error bar represents standard deviation of triplicates. 
Similar results were obtained in three independent biological experiments.
Measurements of c-Myc stability and degradation
Raw264.7 or TLR4/MD2/CD14 293 cell lines were primed with 100ng/ml LPS for 24 hours, 
and then treated with 1μg/ml CHX (cycloheximide, sigma-aldrich #C4859) for indicated 
time. Cells were harvested and subjected to immunoblot analysis by using anti-c-Myc 
antibody. Exposed films of immunoblot were scanned and quantified by ImageJ 
densitometry software. The intensity of each band was plotted in scatter plot and c-Myc 
half-life was determined on computed curve. Raw264.7cells were primed with 100ng/ml 
LPS for 24 hours and then treated with 10μM MG-132 for time indicated. C-Myc 
accumulation was reflected in immunoblot against c-Myc by short- and long-exposure. β-
ACTIN and γ-Tubulin were represented as loading controls.
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Raw264.7 cells were counted and plated in 6-well cell culture plates respectively with 50, 
100, 200 viable cells in duplicated wells. Cells were primed with 100ng/ml LPS for 48 hours 
to reach the condition of ET and replenished with fresh media. 1μM UNC0638 was 
replenished into the media. After 9-day cell growth, cell colonies were washed with PBS, 
fixed with a mixture of methanol-acetic acid (3:1 in volume ratio) for 10 min, stained with 
10% Giemsa (Ricca) for 30 min, gently washed with water, and air-dried. The colonies 
containing more than 20 cells were counted and the percentage of the survived cells under 
each condition was determined compared to the number of colonies on non-LPS or 
UNC0638-treated plates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Quantitative ChaC for systems dissection of the functional G9a interactome or complexome 
formed within the chromatin of differentially inflamed macrophages. (a) Work-flow of the 
activity-based ChaC with immobilized UNC0638 coupled with AACT/SILAC quantitative 
proteomics. Equal amounts of nuclear extract from each set of BMDMs were incubated with 
Sepharose conjugated with UNC0638 or UNC2249 and the pull-down products were mixed 
and subjected to LC-MS/MS. (b) Immunoblot analysis of the G9a pulled down by 
UNC2249 from the BMDMs under different inflammatory conditions (N, NL, and TL). 
Upper bands indicate the long-isoform of G9a while the lower bands are the shorter forms. 
β-ACTIN is the loading control. Same in figures below: all full blots are in Supplementary 
Figure 14. (c) Scatter plot of the pull-down proteins with TL/N and NL/N ratio measured by 
AACT-based quantitative ChaC. The insets indicate previously known G9a interactors with 
their ratios to determine the threshold of NL- or TL-specific interactors. (d) Protein-protein 
interaction network of TL-specific G9a-interacting protein complexes, determined by 
STRING in high confidence (The confidence score is at 0.7).
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Recruitment of TL-specific G9a associates to the chromatin of T-class gene promoters is 
G9a-dependent. ChIP assay was performed in (a, upper) paired wild-type vs. G9a KD 
Raw264.7 cells, with the antibody against HDAC1, (a, lower) ChIP assay against HDAC1 in 
BMDMs with or without UNC0638 treatment. (b) ChIP assay against G9a antibody in 
BMDMs with or without SAHA treatment. ChIP assay was performed in paired wild-type 
vs. G9a KD Raw264.7 cells, with the antibody against Brg1 (c), CtBP2 (d), MTA1 (e), YY1 
(f) to measure their binding to IL6 proximal promoter (‘Cc’) and intragenic (‘Ee’) regions. 
Empty vector (EV) served as the control line. Same in figures below: error bars that 
represent the mean of triplicates were obtained as the follows: A upper error bar was 
determined by 2−(dCt−SD) − 2− (dCt), and the lower one was by 2−(dCt) − 2− (dCt+SD). (*) The 
p value (<0.05) gives the statistical significant difference of ChIP-PCR enriched gene 
between two defined cell conditions according to two-tails unpaired Student’s t-test. (**) p 
value<0.01 (g) The co-regulatory network is composed of multiple transcription factors 
identified by ChaC and their downstream genes identified by G9a-dependent quantitative 
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proteomics. Rectangles represent transcription factors and filled circles represent targeting 
genes.
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Chronic-active G9a interacts with select HMTases during ET. NSD3 (a) and ASH2L (d) 
specifically interact with chronically active G9a in LPS-tolerant 293-TLR4/CD14/MD2 
cells. Cell responses were monitored by p65 phosphorylation. (b) Lysine methylation at 
multiple sites on H3 were compared in paired wild-type or G9a KD Raw264.7 cells (left) 
and in BMDMs with or without 2-day UNC0638 treatment (right). Unmodified H3 was used 
as the loading control. (c) ChIP assay of NSD3 deposition on IL6 ‘Cc’ and ‘Ee’ region in the 
same sample pairs as (b). (*) p value<0.05; (**) p value<0.01. Two-tails unpaired Student’s 
t-test. (e) Immunoblot analysis of the pulled down products from a paired wild-type vs. G9a 
KD Raw264.7 cells under TL using histone H3 lysine 4 methylated peptides.
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Chronically active G9a forms a stable complex during endotoxin tolerance. (a) IFI35 
remained active in LPS-tolerant cells. mRNA expression was normalized to GAPDH. The 
release of TNFα indicates the strength of immune response. (**) p value<0.01. Two-tails 
unpaired Student’s t-test. (b) and c-Myc (d) specifically interact with G9a in LPS-tolerant, 
TLR4/CD14/MD2 293 cells. (c) IFI35 interacts with the catalytic SET domain of G9a in TL 
cells as assayed by IP with HA-tagged SET (upper), and vice versa (lower). (e) NMI, IFI35, 
c-Myc and G9a were co-immunoprecipitated from LPS-tolerant cells. (f) Both IFI35 and c-
Myc associate with the peptide containing H3K9me2 in the complex with G9a. (g) c-Myc 
promotes the HMTase activity of G9a. c-Myc and G9a were co-transfected into LPS-
tolerant, TLR4/CD14/MD2 293 cells, and c-Myc was enriched for the H3K9 HMTase 
activity assay. ‘NTC’ refers to non-transfected control cells, EV is the empty vector control, 
HA-G9a represents the IP background, and FLAG-G9a is a positive control for HMTase 
activity. Recombinant G9a (rG9a) is a positive control for in vitro reactions, and the 
reactions either without enzyme (W/O E) or without S-adenosyl methionine (W/O SAM) are 
negative controls. (h) G9a significantly repressed NF-κB reporter genes in a dose-dependent 
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manner in cooperation with c-Myc. All luciferase assays were performed with three 
individual preparations. Values and error bars indicate the mean and S.D. among biological 
triplicates. The ectopic proteins were detected by immunoblotting. β-ACTIN is the loading 
control.
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Genomic mapping of G9a-dependent c-Myc binding targets. (a) Schematic Venn diagram 
represents the overlap of c-Myc binding genes between G9a KD and the wild-type (EV) 
cells. c-Myc binding peaks located between 10 kb upstream from the start site and 10 kb 
downstream from the stop site of annotated transcripts are considered as gene-relevant 
bindings. (b) Gene ontology biological process analysis indicates the clusters over-
represented in the c-Myc binding genes from G9a KD and wild-type cells, respectively. (c) 
Representative images depict c-Myc ChIP-seq binding profiles on IL10 genome (upper). c-
Myc deposition was validated by ChIP assay on IL10 distal and proximal promoter regions 
in G9a KD and wild-type cells (lower). (d) ChIP assay of c-Myc binding on IL6, IP-10, p21 
and Fpr1 promoters in G9a KD and wild-type cells. (*) p value<0.05; (**) p value<0.01. 
Two-tails unpaired Student’s t-test.
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Chronically active G9a stabilizes c-Myc and promotes cell survival. (a) c-Myc protein 
expression was diminished in G9a KD cells under TL conditions. The abundance of G9a 
was measured to determine G9a knockdown efficiency and β-ACTIN was the loading 
control. (b) c-Myc mRNA expression was elevated in G9a KD, LPS-tolerant cells, 
represented by the relative expression normalized to GAPDH. (c) c-Myc half-life was 
measured in wild-type (EV) and G9a KD tolerant cells treated with CHX in a time-
dependent manner. The intensities of c-Myc are shown as Y value in the scatter plot, and c-
Myc half-life was indicated by crossing dashed line with X axis. γ-tubulin is the loading 
Liu et al. Page 31













control. (d) c-Myc accumulation was investigated by applying a time-course MG-132 
treatment on LPS-tolerant cells. (e) Activated G9a is required to maintain cell survival in 
tolerant cells. Cell viability was measured as survival percentage normalized to non-treated 
naïve cells. (**) p value<0.01. Two-tails unpaired Student’s t-test.
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The mechanistic models of G9a-dependent, gene-specific regulation of transcription (a) c-
Myc is a dual-functional transcription factor dependent upon either an acetyl-lysine or 
methyl-lysine-enriched environment when chronically active G9a promotes its 
transcriptional activity to repress select genes. (b) chronically active G9a selectively recruits 
defined protein complexes into the chromatin of proinflammatory genes for their silencing 
during endotoxin tolerance.
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